标题: 专注于代谢和内分泌疾病的临床阶段生物制药公司Lipocine Inc. [打印本页] 作者: StephenW 时间: 2019-10-2 15:37 标题: 专注于代谢和内分泌疾病的临床阶段生物制药公司Lipocine Inc.
SALT LAKE CITY, Oct. 1, 2019 /PRNewswire/ -- Lipocine Inc. (LPCN), a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders, announced today that data from a clinical trial of LPCN 1144 in non-alcoholic fatty liver disease ("NAFLD") will be presented at The Liver Meeting® 2019. The Liver Meeting® 2019, which is the annual meeting of the American Association for the Study of Liver Diseases ("AASLD"), a leading organization of scientists and healthcare professionals committed to preventing and curing liver disease, will be held on November 8th – 12th in Boston, Massachusetts. Lipocine's abstract has been selected by the Scientific Program Committee of the AASLD as a Poster of Distinction for presentation.
(PRNewsfoto/Lipocine Inc.)
(PRNewsfoto/Lipocine Inc.)
Lipocine Inc. is a clinical-stage biopharmaceutical company focused on metabolic and endocrine disorders using its proprietary drug delivery technologies. Lipocine's clinical development pipeline includes TLANDO, LPCN 1144, TLANDO XR (LPCN 1111), LPCN 1148 and LPCN 1107 development programs. TLANDO, a novel oral prodrug of testosterone containing testosterone undecanoate, is designed to help restore normal testosterone levels in hypogonadal men and currently under USFDA review for marketing approval. LPCN 1144, a differentiated oral product of bioidentical testosterone, is currently undergoing Phase 2 clinical testing in biopsy confirmed NASH patients and recently completed a proof-of-concept clinical study demonstrating the potential utility the in treatment of NASH. TLANDO XR (LPCN 1111), a novel oral prodrug of testosterone, originated and is being developed by Lipocine as a next-generation oral testosterone product with potential for once-daily dosing and has completed Phase 2 testing. LPCN 1148 is a unique oral testosterone product targeted to treat NASH cirrhosis. LPCN 1107 is potentially the first oral hydroxyprogesterone caproate product candidate indicated for the prevention of recurrent preterm birth and has been granted orphan drug designation by the FDA. An End of Phase 2 meeting with the FDA has been completed. For more information, please visit www.lipocine.com.作者: StephenW 时间: 2019-10-2 15:37